SAB Biotherapeutics SABS
NASDAQ SABS
$3.01 -0.05 (-1.63%)
As of: Oct 2, 2026 · 10:18 AM EDT

SAB Biotherapeutics (SABS) Long-Term Investments (2021 - 2026)

Updated

SAB Biotherapeutics (SABS) reported Long-Term Investments of $105.35 million for Q2 2026, down 4.4% from the prior quarter.

Analysis

SAB Biotherapeutics (SABS) Long-Term Investments (2021 - 2026) Analysis & Trends

At the end of FY2025, SAB Biotherapeutics posted Long-Term Investments of $46.89 million.

  • Five-year quarterly Long-Term Investments spans a low of $1.24 million in Q1 2024 and a high of $116.16 million in Q3 2021.
  • Per Business Quant data, the three quarters before Q2 2026 came in at $110.24 million (Q1 2026), $46.89 million (Q4 2025) and $50.61 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 266.00 Mn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 1.22 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 69.00 Mn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 2.62 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 1.56 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 5.79 Bn
10 SAB Biotherapeutics 264.67 Mn 264.67 Mn - 105.35 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 105.35 Mn
Mar 31, 2026 110.24 Mn
Dec 31, 2025 46.89 Mn
Sep 30, 2025 50.61 Mn
Mar 31, 2024 1.24 Mn
Sep 30, 2021 116.16 Mn
Jun 30, 2021 116.16 Mn
Mar 31, 2021 116.15 Mn
API Access

SAB Biotherapeutics Long-Term Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-investments&ticker=SABS&period=max&api_key=YOUR_API_KEY